|
 AT First Diagnostic’s market success has come from a broad acceptance of the performance of its products by clinical laboratory professionals. All of First Diagnostic’s products are based on the same unique flow-through membrane technology, which relies on highly specific antigen-antibody reactions allowing for the detection of disease-specific markers in clinical specimens. In our rapid tests, a special membrane is coated with disease-specific antigens or antibodies to capture the corresponding marker in the test sample, thus allowing for the detection of the disease. The simple testing procedure involves placing a drop of the test sample on the coated test membrane and allowing it to flow through the membrane. If the sample contains the target antibodies or antigens, they are captured on the test membrane and result in a highly specific antigen-antibody complex. The test result is visualized at a colored line through a reaction with a proprietary detection agent and can be interpreted immediately.
 AT First Diagnostic deploys its unique micro flow-through testing platform; including a single buffer solution for preparation and performance of the test and unique colorimetric agent, which allows for a visual interpretation of test results. The testing procedure is completed within minutes. Precision pipetting, sample manipulation or specialized equipment is not required to perform any of First Diagnostic’s rapid tests, making it an invaluable diagnostic resource in laboratories that are space and time limited.
 Multiple ApplicationsAT First Diagnostic’s market-proven, flow-through membrane technology platform can be used quickly and efficiently to develop tests for many diseases, from smallpox to emerging diseases such as avian influenza. First Diagnostic develops disease-specific rapid tests based on its proprietary technology, making all test procedures similarly simple and user-friendly. As a result, First Diagnostic is able to develop and market reliable, high-quality tests for other diseases quickly, and ensure ready acceptance and use by medical laboratories.
Coming in 2008; The ROS Protein Platform is First Diagnostics new patent pending rapid test technology. First Diagnostic has signed an exclusive license agreement for a first-of-its-type fluorescence technology for the retail rapid test kit marketplace, the new development is a highly sensitive immunoassay that is a breakthrough in the sensitivity limitation of rapid one-step lateral flow immunoassay. This platform retains the technical edge of conventional rapid one-step immunoassay and adds the performance of highly sophisticated and expensive instrument-reliant test systems.
Since it is 50-1000 times more sensitive than current rapid one-step assays, ROS Protein Platform will allow First Diagnostic to penetrate market segments in front of other established companies. These segments have been inaccessible by the current version of rapid assays primarily due to their limitations in sensitivity. The Companys partner has filed a patent application and expects to market ROS Protein Platform products.
The ROS Gene POCT Platform is being developed in two different formats for a more integrated, interdisciplinary approach to developing a new area of diagnostics that will have future worldwide market demand. ROS Gene POCT I is the one-step lateral flow technology that is based on PCR-based methodology for the selective amplification of DNA or RNA target sequences. With this technology, current threats such as the West Nile Virus and the Dengue Virus as well as other Flaviviruses will become possible to detect with employment of ready-to-use PCR kits and POCT devices that do not require expensive, real-time detection instruments.
ROS Gene POCT I will also set the foundation for the development of much needed sexually transmitted disease (STD) and Biological Warfare panels. ROS Gene POCT II platform will enable the detection of low concentrations of specific genomic DNA sequences from biological pathogens, potentially down to a single nucleotide, with or without an integrated PCR reaction.
We expect to be highly competitive in the market due to our scientists’ ability to process reagents in conjunction with their expertise in producing high quality end-products in various diagnostic applications for genetic diseases, cancer prognosis, individual identifications, infectious disease identifications, and others.
|
